ASP6432

Research use only, not for human use.

ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM.

ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM; also inhibits the LPA-induced [Ca2+]i increase in cells expressing rat LPA1 (IC50=30 nM), weakly inhibits LPA-induced [Ca2+]i increase in cells expressing human LPA4 (IC50=114 nM), and shows no activity on LAP2/3; inhibits LPA-induced urethra and prostate contractions in isolated rat tissue strips and anesthetized rats, decreases the urethral perfusion pressure (UPP) anesthetized rats.Other Indication Phase 1 Discontinued.

ASP6432 inhibits the LPA-induced proliferation of human prostate stromal cells.

——

ASP 6432 | ASP-6432

GPCR/G Protein

Lysophospholipid Receptor

Lysophospholipid Receptor

Other Indications

Other Disease

1282549-08-9

598.774

C26H31KN4O6S2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (417.52 mM)

O=C(C1=CC(OC)=C(O)C(OC)=C1)N(CC2=[S]C=C(C(N(S(=O)(NCC)=O)[K])=O)[N]2)CCCC3=CC=CC=C3

2-((3,5-dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido)methyl)-N-(N-ethylsulfamoyl)thiazole-4-carboxamide, potassium salt

(-20℃)

With Ice Pack

≥ 2 years